» Articles » PMID: 36685879

Non-coding RNA and Autophagy: Finding Novel Ways to Improve the Diagnostic Management of Bladder Cancer

Overview
Journal Front Genet
Date 2023 Jan 23
PMID 36685879
Authors
Affiliations
Soon will be listed here.
Abstract

Major fraction of the human genome is transcribed in to the RNA but is not translated in to any specific functional protein. These transcribed but not translated RNA molecules are called as non-coding RNA (ncRNA). There are thousands of different non-coding RNAs present inside the cells, each regulating different cellular pathway/pathways. Over the last few decades non-coding RNAs have been found to be involved in various diseases including cancer. Non-coding RNAs are reported to function both as tumor enhancer and/or tumor suppressor in almost each type of cancer. Urothelial carcinoma of the urinary bladder is the second most common urogenital malignancy in the world. Over the last few decades, non-coding RNAs were demonstrated to be linked with bladder cancer progression by modulating different signalling pathways and cellular processes such as autophagy, metastasis, drug resistance and tumor proliferation. Due to the heterogeneity of bladder cancer cells more in-depth molecular characterization is needed to identify new diagnostic and treatment options. This review emphasizes the current findings on non-coding RNAs and their relationship with various oncological processes such as autophagy, and their applicability to the pathophysiology of bladder cancer. This may offer an understanding of evolving non-coding RNA-targeted diagnostic tools and new therapeutic approaches for bladder cancer management in the future.

Citing Articles

Human β-defensin-1 activates autophagy in human colon cancer cells regulation of long non-coding RNA TCONS_00014506.

Eid N, Davamani F World J Gastrointest Oncol. 2024; 16(7):2894-2901.

PMID: 39072156 PMC: 11271776. DOI: 10.4251/wjgo.v16.i7.2894.


Non-coding RNA and reprogrammed mitochondrial metabolism in genitourinary cancer.

Thirunavukkarasu S, Banerjee S, Tantray I, Ojha R Front Genet. 2024; 15:1364389.

PMID: 38544804 PMC: 10965626. DOI: 10.3389/fgene.2024.1364389.


PTBP1 as a potential regulator of disease.

Yu Q, Wu T, Xu W, Wei J, Zhao A, Wang M Mol Cell Biochem. 2023; 479(11):2875-2894.

PMID: 38129625 DOI: 10.1007/s11010-023-04905-x.

References
1.
Zhang X, Zhang Y, Liu X, Fang A, Li P, Li Z . MicroRNA-203 Is a Prognostic Indicator in Bladder Cancer and Enhances Chemosensitivity to Cisplatin via Apoptosis by Targeting Bcl-w and Survivin. PLoS One. 2015; 10(11):e0143441. PMC: 4657877. DOI: 10.1371/journal.pone.0143441. View

2.
Mirzaei S, Paskeh M, Hashemi F, Zabolian A, Hashemi M, Entezari M . Long non-coding RNAs as new players in bladder cancer: Lessons from pre-clinical and clinical studies. Life Sci. 2021; 288:119948. DOI: 10.1016/j.lfs.2021.119948. View

3.
Li Z, Yu D, Li H, Lv Y, Li S . Long non‑coding RNA UCA1 confers tamoxifen resistance in breast cancer endocrinotherapy through regulation of the EZH2/p21 axis and the PI3K/AKT signaling pathway. Int J Oncol. 2019; 54(3):1033-1042. DOI: 10.3892/ijo.2019.4679. View

4.
Zhu Y, Liang Z, Li S, Xu X, Wang X, Wu J . c-Met and CREB1 are involved in miR-433-mediated inhibition of the epithelial-mesenchymal transition in bladder cancer by regulating Akt/GSK-3β/Snail signaling. Cell Death Dis. 2016; 7:e2088. PMC: 4849142. DOI: 10.1038/cddis.2015.274. View

5.
Trujano-Camacho S, Leon D, Delgado-Waldo I, Coronel-Hernandez J, Millan-Catalan O, Hernandez-Sotelo D . Inhibition of Wnt-β-Catenin Signaling by ICRT14 Drug Depends of Post-Transcriptional Regulation by HOTAIR in Human Cervical Cancer HeLa Cells. Front Oncol. 2021; 11:729228. PMC: 8580948. DOI: 10.3389/fonc.2021.729228. View